NCT00749684View on ClinicalTrials.gov

Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083)

CompletedOBSERVATIONAL

Enrollment

138

Participants

Timeline

Start Date

December 31, 1996

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions

Melanoma

Interventions

BIOLOGICAL

Interferon α-2b

20 mio IU/m² interferon-α-2b 5x/week intravenously (IV) over the course of 1 month, followed by 10 mio IU/m² interferon-α-2b 3x/week subcutaneously (SC) for 11 months.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00749684 - Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083) | Biotech Hunter | Biotech Hunter